“Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch Vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison”. SKIN The Journal of Cutaneous Medicine, vol. 10, no. 2, Mar. 2026, p. s738, https://doi.org/10.25251/0bwr4a20.